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Abstract 
The intestinal epithelium represents one of our most important interfaces with the external 
environment. It must remain tightly balanced to allow nutrient absorption, but maintain barrier 
function and immune homeostasis, a failure of which results in chronic infection or debilitating 
inflammatory bowel disease. The intestinal epithelium mainly consists of absorptive enterocytes 
and secretory goblet and Paneth cells, and has recently come to light as being an essential 
modulator of immunity as opposed to a simple passive barrier. Each epithelial subtype can 
produce specific immune modulating factors, driving innate immunity to pathogens as well as 
preventing autoimmunity. The enteroendocrine cells comprise just 1% of this epithelium, but 
collectively form the bodies’ largest endocrine system. The mechanisms of enteroendocrine cell 
peptide secretion during feeding, metabolism and nutrient absorption are well studied; but their 
potential interactions with the enriched numbers of surrounding immune cells remain largely 
unexplored.  
This review focuses on alterations in enteroendocrine cell number and peptide secretion during 
inflammation and disease, highlighting the few in depth studies which have attempted to dissect 
the immune driven mechanisms that drive these phenomena. Moreover, the emerging potential 
of enteroendocrine cells acting as innate sensors of intestinal perturbation and secreting 
peptides to directly orchestrate immune cell function will be proposed.  
In summary, the data generated from these studies have begun to unravel a complex cross-talk 
between immune and enteroendocrine cells, highlighting the emerging immunoendocrine axis 












chemokine (C-X-C motif) ligand (CXCL), cholecystokinin (CCK), Crohn’s disease (CD),  
dendritic cells (DCs), dextran sulfate sodium (DSS), glucagon-like peptide 1and 2 (GLP-1, GLP-
2), glucose dependent insulinotropic peptide (GIP), G protein-coupled receptors (GPRs),  
inflammatory bowel disease (IBD), interleukin (IL), lipopolysaccharide (LPS), mitogen-activated 
protein kinase (MAPK), peptide YY (PYY), severe combined immunodeficiency (SCID), 
serotonin (5-HT), T-helper (Th), Toll like receptors (TLRs), , 2,4,6-trinitrobenzenesulfonic acid 
(TNBS), ulcerative colitis (UC). 
 
Summary Statement 
The intestinal epithelium plays a crucial role in maintaining barrier function and immune 
homeostasis, a failure of which results in disease. This review focuses on the epithelial 
enteroendocrine cells and the crosstalk that exists with immune cells during inflammation.   
 
Introduction 
Dispersed throughout the intestinal epithelium are the enteroendocrine cells which, despite only 
comprising 1% of the epithelium, collectively form the largest endocrine system in humans. 
Enteroendocrine cells respond to luminal nutrients by secreting >20 peptide hormones, 
including cholecystokinin (CCK), glucagon-like peptide 1 and 2 (GLP-1, GLP-2), glucose 
dependent insulinotropic peptide (GIP), peptide YY (PYY), somatostatin and ghrelin; as well as 
bioactive amines such as serotonin (5-HT). The historical dogma of differentiated 
enteroendocrine cellular subtypes secreting distinct hormone peptides has been superseded, 
via the use of transgenic reporter mice, to the recognition that enteroendocrine cells can secrete 
a comprehensive array of peptide hormones altering based on their location within the gut[1]. 
These secreted peptide hormones act on distant organs such as pancreatic islets or locally on 
neighbouring cells such as enterocytes and vagal nerve endings. Enteroendocrine cells have 
classically been studied for their roles in enabling efficient postprandial assimilation of nutrients 
via endocrine and paracrine induced alterations in gastrointestinal secretion, motility, pancreatic 
insulin release and satiety[2].  
The key feature of enteroendocrine cells is to sense luminal nutrients and bring about the ideal 
absorption conditions for the particular nutrients detected. Classical examples of this fine tuning 
in nutrient detection are the enteroendocrine I-cells of the duodenum. In response to sensing 
long-chain fatty acids via activation of G protein-coupled receptors (GPRs); I-cells undergo Ca2+ 
flux and membrane depolarisation, culminating in secretion of the hormone CCK. CCK acts 
through the CCK receptor to cause gall bladder contraction and pancreatic enzyme secretion 
allowing efficient assimilation of the long chain fatty acids detected[3]. Further to mediating 
digestion and metabolism, secreted hormones can also terminate meal size by vagally 
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triggering satiation in feeding centres of the brain[2]. Therefore, clinical trials are focussing on 
the use of enteroendocrine peptide receptor agonists for the therapeutic treatment of obesity 
and metabolic diseases[2]. Of particular note is the use of GLP-1 receptor agonists for the 
treatment of diabetes, following the key observation that the incretin GLP-1 is anti-apoptotic for 
pancreatic beta-cells[4].  
Intriguingly, both murine and human studies have demonstrated alterations in enteroendocrine 
cell number and secretion during inflammation[5, 6] and the vast immune system that serves the 
gut has been shown to express an array of enteroendocrine cell peptide receptors[7]. 
Furthermore, in vitro/vivo studies have demonstrated that enteroendocrine cells possess 
functional Toll like receptors (TLRs)[8] and can directly respond to metabolites produced from 
commensal bacteria[9]. These observations indicate that enteroendocrine cells may have direct 
and critical roles in orchestrating intestinal immune responses to both pathogens and 
commensal bacteria (Fig. 1) and despite the ongoing therapeutic trials and use of 
enteroendocrine cell peptide receptor agonists; few studies have examined the potential 
importance of this immunoendocrine axis.  
This review will focus on alterations in enteroendocrine number and peptide secretion during 
inflammation and disease, highlighting in depth mechanistic mouse model studies. Furthermore, 
the emerging potential of enteroendocrine cells acting as innate sensors of pathogens and 
perturbations in the intestinal microbiome will be discussed; identifying enteroendocrine cells as 
key orchestrators of intestinal immunity. 
 
Enteroendocrine cells and inflammatory bowel disease  
Given that reduced feeding, anorexia, and altered intestinal motility often accompany intestinal 
inflammation, it is surprising that enteroendocrine cells, as key instigators of these changes 
during homeostasis, have been neglected as possible orchestrators of these pathologies during 
disease. However, recent genome-wide association studies for Crohn’s disease (CD) have 
identified a single nuclear polymorphism in the enteroendocrine associated homeodomain 
transcription factor Phox2B [10]. This coupled with the detection of autoantibodies for the 
ubiquitination factor E4A specifically in enteroendocrine cells during Crohn’s [11], has brought 
some focus upon the possible role of enteroendocrine cells in the pathogenesis of inflammatory 
bowel disease (IBD). Indeed, alterations in enteroendocrine cell numbers and secretion have 
been noted during IBD; with increased PYY and 5-HT cells in lymphatic colitis, reduced colonic 
PYY cells in both CD and ulcerative colitis (UC), increases in GLP-1 and PYY cell number in 
terminal ileal CD and increases in GLP-2 in both CD and UC[5]. GLP-2 is a well-known 
epithelial growth factor with additional anti-inflammatory properties, including aiding secretion of 
anti-bacterial peptides from Paneth cells [12], and is therefore the most simplistic example of 
enteroendocrine function influencing intestinal disease pathology. Indeed, GLP-2 has been 
shown to be protective in animal models of IBD[13] and long acting analogs of GLP-2 are 
currently on trial for the treatment of CD[14]. Despite this beneficial change in enteroendocrine 
function during IBD, the reduced appetite, anorexia and nausea associated with IBD is also 
likely to be driven by altered enteroendocrine function. Although increases in GLP-1 in UC are 
not thought to be responsible for any changes in feeding patterns, due to unaltered gastric 
emptying; small bowel Crohn’s associated feeding decreases and nausea do correlate with 
increased PYY levels [5]. Furthermore, increased enteroendocrine numbers in long standing UC 
have been suggested to act as promoters for the neoplasia associated with IBD[15], while 
recent data has demonstrated enteroendocrine cells as being key producers of the pro-
inflammatory cytokine IL-17C during CD and UC, possibly playing a key role in disease 
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progression [16] . Taken together this suggests that enteroendocrine cells play an essential and 
varied role in the pathology of IBD and are strong candidates for therapeutic intervention.  
 
Enteroendocrine cells in mouse models of IBD 
Further mechanistic study of the pathways involved in enteroendocrine cell pathology during 
IBD has been made possible via the use of animal models of intestinal inflammation. Colitis can 
be induced chemically via the administration of dextran sulfate sodium (DSS) or 2,4,6-
trinitrobenzenesulfonic acid (TNBS) and both models are well associated with reduced feeding 
and weight loss. Interestingly, it has been reported that the feeding alterations seen in TNBS 
induced colitis are likely due alterations in enteroendocrine satiety as opposed to simple 
malaise, due to changes in gastric emptying[17]. Guinea pigs with TNBS-induced colitis have 
been shown to have hyperplasia of 5-HT and GLP-2 enteroendocrine cells. Through the use of 
BrdU labelling of proliferative cells it has been demonstrated that, although a small capacity of 
5-HT producing enterochromaffin cells retain proliferative capacity, the majority of hyperplasia is 
due to alterations in the stem cell niche[18]. As all epithelial cells arise from the same pluripotent 
stem cell[6], this is suggestive that alterations in enteroendocrine number occur at the stem cell 
level, and due to the high turnover of intestinal epithelial cells can quickly influence the 
inflammatory state. These chemical induced colitis models have been particular useful in 
establishing the role of enteroendocrine cells in the pathogenesis of mouse models of disease. 
Further elucidations have been made utilizing infection based models of intestinal inflammation, 
which have demonstrated a key role for enteroendocrine cells during infection; as well as 
offering translational lessons for IBD. 
 
Enteroendocrine cells as mediators of intestinal infection 
There are numerous reports of alterations in enteroendocrine cell number and secretion during 
a variety of infectious agents in a diverse range of animals. For example decreased 
somatostatin positive cells are seen during schistomiasis in mice[19], while increases in CCK 
positive cells occur in Giardia infected humans[6] and Myxozoa infected fish[20]. Many studies 
within the livestock industry have associated changes in enteroendocrine function with weight 
loss during intestinal infection. Infection with the intestinal parasites Ascaris suum in pigs and 
Trichostrongylus colubriformis in lambs results in hypophagia that is coupled with an increase in 
CCK[6]; while increased 5-HT and CCK enteroendocrine cells significantly correlate with the 
cachexia seen in Enteromyxum scophthalmi infected Turbot[20]. Animal models have been 
particularly useful for dissecting the mechanisms responsible for the hyperplasia of 
enteroendocrine cells during inflammation with studies suggesting an immune driven alteration. 
There is a close physical association of immune cells with enteroendocrine cells[21] and the 5-
HT hyperplasia observed during Citrobacter rodentium infection is absent in severe combined 
immunodeficiency (SCID) mice[22], which lack adaptive immunity. 
We have carried out in depth studies with the helminth Trichinella spiralis which causes a well 
characterised transient enteritis and weight loss in mice, with parasite expulsion dependent on T 
helper (Th) 2 cytokines and mastocytosis[23]. Utilising a variety of transgenic mice we have 
dissected the molecular mechanisms and actual function of the hypophagia seen during this 
parasitic infection. Intriguingly both CCK+ cell hyperplasia[23] and CCK hypersecretion[24] are 
observed during T. spiralis infection and this correlates with the period of hypophagia seen 
during enteritis. Furthermore, the absence of CD4+ T-cells or the CCK signalling pathway 
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results in a complete lack of hypophagia during enteritis[23, 24], while the adoptive transfer of 
CD4+ T-cells to infected SCID mice restores the otherwise absent hypophagia[23]. Collectively 
this indicates that the adaptive immune system hijacks classical feeding pathways to reduce 
food intake during infection. We further pursued the possible benefit of such a mechanism, 
beyond a simple innate device to prevent continued feeding at an infected site, by examining if 
reduced feeding was in any way beneficial to the host in coping with the parasitic burden. The 
period of immune mediated-CCK induced hypophagia during infection resulted in a significant 
reduction in weight and visible reduction in visceral fat pads, a rich source of immune 
manipulating adipokines, most notably leptin[25].  We therefore postulated that the immune 
driven reductions in leptin, a strong Th1 inducing adipokine[25], could be beneficial in allowing 
the helminth expelling Th2 immune response to develop, allowing parasite expulsion. To 
investigate such an effect we restored basal leptin levels throughout infection induced 
hypophagia via the injection of recombinant leptin and saw a significant reduction in CD4+ T-cell 
Th2 cytokine production and mastocytosis, culminating in a significant reduction in parasite 
expulsion. Hence, we have identified immune driven alterations in enteroendocrine feeding 
pathways, as a novel mechanism in helminth expulsion[23]. 
Parallel studies have demonstrated CD4+ T-cell control of 5-HT producing enterochromaffin 
cells during a large intestinal helminth infection, which is thought to be driven at the 
enterochromaffin cell level via the expression of interleukin (IL)-13Ralpha1 expression[26]. 
Indeed, CD4+ Th2 cytokines are essential for these alterations, as a chronic dose of the same 
helminth, resulting in a Th1 immune response does not drive the enterochromaffin 
hyperplasia[27].  Although the precise function of these changes has not been defined, 5-HT 
has many possible immune modulating abilities[28], and could therefore again be an adaptively 
driven mechanism of parasite expulsion. The possibility IL-13 is responsible for the alterations in 
CCK  seen during T. spiralis infection is less likely,  given the ample, NK cell-derived, IL-13 
induced goblet cell hyperplasia observed in infected SCID mice , but lack of accompanying I-cell 
hyperplasia[23]. This uncoupling of enteroendocrine differentiation during inflammation holds 
promising therapeutic potential, given the diverse potential functional roles of individual 
enteroendocrine peptide hormones.  
 
Direct immunomodulatory roles of enteroendocrine cells  
Intriguingly, immune cells express a vast array of receptors for enteroendocrine secreted 
hormone peptides[7] suggesting an exciting potential of  bi-directional signalling in the 
immunoendocrine axis. The production of the amine 5-HT from enterochromaffin endocrine cells 
is well established as a direct immunomodulatory factor, with the 7 receptor isoforms expressed 
on mast cells, monocytes, dendritic cells (DCs), eosinophils, T and B-cells and neutrophils[28]. 
Immune cells can also produce 5-HT independently of endocrine cells and the effect on immune 
cells is varied from cellular recruitment, activation, phagocytosis, antigen presentation and 
cytokine secretion[28]. Recent and ongoing studies are dissecting the potential for peptide 
hormones to influence immunity in a similar manner to the well-studied actions of 5-HT. Indeed, 
carboxypeptidase E null mice, an enteroendocrine associated exopeptidase essential for 
processing and packaging endocrine peptides, demonstrate increased IL-6 and chemokine (C-
X-C motif) ligand (CXCL) 1 and exacerbated DSS induced colitis[29].      
CCK octapeptide has been shown to inhibit toll like receptor (TLR9) stimulation of plasmacytoid 
DCs via tumour necrosis factor receptor-associated factor 6 signalling[30], while it can promote 
IL-12 production from DCs and reduce IL-6 and IL-23 production offering protection during 
collagen induced arthritis[31]. CCK octapeptide can also directly affect T and B-cells and has 
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been shown to promote a Th2 and regulatory T-cell phenotype in vitro[32], promote IL-2 
production in the Jurkat T-cell line[33], stimulate B-cells to produce acetylcholine[34] and reduce 
B-cell lipopolysaccharide (LPS) induced activation[35]. Strikingly, the huge atrophy in lymphoid 
tissue, including Peyer’s patches, IgA production and total cellularity, seen during parenteral 
feeding can be rescued via the infusion of CCK alone[7], functionally rescuing immune 
responses to infectious bacteria[36]. 
Other promising immunomodulatory enteroendocrine hormone peptides include the orexigenic 
peptide ghrelin. Ghrelin increases T cell proliferation via phosphoinositide 3-kinase, 
extracellular-signal-regulated kinases and protein kinase C[37] and has been shown to have an 
anti-inflammatory effect in DSS-induced colitis [38]. Interestingly ghrelin actually has direct anti-
parasitic[39] and anti-bacterial effects[40]. Similarly to 5-HT, T-cells themselves can produce 
ghrelin that is involved in anti-inflammatory responses in terms of reducing Th1 and Th17 
responses[41]. Moreover, somatostatin is inhibitory to T cell proliferation[42], GLP-1 also has 
anti-inflammatory effects on T cells via decreased mitogen-activated protein kinase (MAPK) 
activation [43] and may modulate regulatory T cells[44]. Indeed, intraepithelial lymphocytes 
respond to GLP-1 to influence the response to DSS-induced colitis [45]. 
 
Enteroendocrine cells are also direct sources of cytokines; being key producers of the pro-
inflammatory cytokine IL-17C during CD and UC [16]. Enteroendocrine cells have been shown 
to express functional TLRs, in vitro and in vivo studies have shown that CCK secreting cells 
express TLR 1, 2 and 4 , with stimulation resulting in increased NF-κβ, MAPK signalling, as well 
as Ca flux culminating in tumour necrosis factor-α, transforming growth factor-β and 
macrophage inhibitory protein 2 as well as CCK release[8]. Indeed, enteroendocrine cells 
appear to be able to modulate their response between pathogenic and nutrient sensing, 
secreting CXCL1/3 and IL-32 in response to flagellin and LPS, but not to fatty acids in vitro [46]. 
Taken together, this indicates that enteroendocrine cells can act as front line pathogen 
detectors releasing either classical cytokines or peptide hormones that can directly orchestrate 
adaptive and innate immunity. 
 
Vagally mediated immunomodulatory roles of enteroendocrine released peptide 
hormones  
As well as being able to directly influence immune cells, enteroendocrine secreted products can 
indirectly influence immune responses via the triggering of vagal afferents. This anti-
inflammatory pathway was first examined during haemorrhagic shock. Nutritional stimulation of 
CCK via a high fat diet protected via a vagal reflex releasing acetylcholine which inhibited pro-
inflammatory cytokine secretion from macrophages [47]. Others have demonstrated similar 
vagal-macrophage regulation in a variety of inflammatory settings[48], with the pathway also 
regulating other innate immune cells[48]. However, these results should be considered in 
parallel with other data demonstrating direct effects of CCK on macrophages, CCK inhibits 
iNOS production by macrophages[49], as well as studies demonstrating direct alteration of 
acetylcholine production by B cells in response to CCK[34]. This anti-inflammatory role of the 
vagus nerve, and therefore enteroendocrine peptide hormone stimulation, is an exciting and 




Enteroendocrine cells as sensors of the intestinal microbiome 
Finally, the current explosion in studies into the intestinal microbiome has not failed in linking 
both enteroendocrine cells and vagal signalling to the billions of bacteria which inhabit our 
intestines. Historic studies have demonstrated germ-free mice have drastically altered 
enteroendocrine cell numbers[50]; while recently it has been shown that enteroendocrine cells 
have specific receptors which can respond to bacterial products. In particular GLP-1 secreting 
cells have receptors for many microbiome metabolites such as GPR41 and 43 for short chain 
fatty acids, TGR5 for bile acids and GPR119 for N-oleoylethanolamide and 2-oleoylglycerol; and 
can secrete GLP-1, GLP-2 and PYY in response to stimulation[9]. It is therefore highly likely that 
our intestinal microbiome is able to influence not only obesity, but our entire immune system via 
regulating the production of immunomodulatory enteroendocrine hormone peptides. 
 
Summary  
In summary, emerging data have begun to demonstrate a huge interaction between 
enteroendocrine cells and the immune system. Enteroendocrine cells can secrete classical 
cytokines as well as hormonal peptides that have the ability to directly and indirectly influence 
the entire breadth of our intestinal immune system. Due to the scarcity of these cells and lack of 
specific markers for purification, this immunoendocrine axis has until recently remained 
neglected. The transgenic reporter models now available have led to a huge potential to fully 
investigate this exciting crosstalk between our intestinal endocrine and immune systems, 
opening up new therapeutic targets and the possibility to utilize current drugs used for metabolic 
syndromes in wider immune inflammatory settings. 
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Figure 1. Enteroendocrine Cells-Key Orchestrators of Intestinal Immunity. 
Enteroendocrine cells make up 1% of the intestinal epithelium and beyond their classical role of 
detecting luminal nutrients they also detect and respond to (1) pathogens via the expression of 
toll like receptors and (2) the intestinal microbiome via the expression of specific receptors for 
the metabolites commensal bacteria produce. (3) In response to pathogens and microbial 
metabolites enteroendocrine cells secrete peptide hormones and classical cytokines to the 
surrounding immune cell rich milieu. In addition to classical cytokine receptors immune cells 
express a vast array of receptors for peptide hormones which have direct immunomodulatory 
effects. (4) Enteroendocrine secreted hormone peptides also signal to vagal afferents triggering 
an anti-inflammatory vagal reflex. The resulting acetylcholine released from vagal efferents 
inhibits inflammatory responses from the surrounding immune cells. (5) Vagal afferent signalling 
also modulates classical feeding pathways resulting in altered fat deposits. This in turn, modifies 
the levels of fat secreted adipokines, such as leptin, influencing immune cell function. (6) CD4+ 
T-cells directly influence the function of peptide hormones via increased secretion and 
hyperplasia of enteroendocrine cells via direct enteroendocrine and indirect stem cell signalling.   
 

